载脂蛋白B与动脉粥样硬化性心血管疾病研究进展
|
摘要
载脂蛋白B在脂类代谢、胆固醇的运输中起关键性的作用,其在心血管疾病、家族性β脂蛋白血症、肥胖等疾病的研究中尤为重要。现对载脂蛋白B独特的基因结构和表达模式、脂蛋白滞留应答中的作用以及与动脉粥样硬化性心血管疾病的相关性和预测作用的研究进展做一综述。
Apolipoprotein B( apo B) plays an essential role in the metabolism of lipids and transport of cholesterol.Apo B is also one of the essential factors in the research of coronary artery disease,familial dysbetalipoproteinemia,obesity and other diseases. This paper reviews the research progress of the apo B gene's peculiar structure and expression patterns,the role of apo B in the lipoprotein response-toretention model and the correlation and prediction of apo B for the atherosclerotic cardiovascular disease.
Apolipoprotein B( apo B) plays an essential role in the metabolism of lipids and transport of cholesterol.Apo B is also one of the essential factors in the research of coronary artery disease,familial dysbetalipoproteinemia,obesity and other diseases. This paper reviews the research progress of the apo B gene's peculiar structure and expression patterns,the role of apo B in the lipoprotein response-toretention model and the correlation and prediction of apo B for the atherosclerotic cardiovascular disease.
引文
[1]Mihaylova B,Emberson J,Blackwell L,et al.The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomized trials[J].Lancet,2012,380(9841):581-590.
[2]Cannon CP,Blazing MA,Giugliano RP,et al.Ezetimibe added to statin therapy after acute coronary syndromes[J].N Engl J Med,2015,372(25):2387-2397.
[3]Robinson JG,Farnier M,Krempf M,et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1489-1499.
[4]Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509.
[5]Hegele RA,Gidding SS,Ginsberg HN,et al.Nonstatin low-density lipoproteinlowering therapy and cardiovascular risk reduction-statement from ATVB Council[J].Arterioscler Thromb Vasc Biol,2015,35(11):2269-2280.
[6]Williams KJ,Tabas I,Fisher EA.How an artery heals[J].Circ Res,2015,117(11):909-913.
[7]Borén J,Williams KJ.The central role of arterial retention of cholesterol rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis:a triumph of simplicity[J].Curr Opin Lipidol,2016,27(5):473-483.
[8]Tannock LR.Proteoglycan-LDL interactions:a novel therapeutic target?[J].Atherosclerosis,2014,233(1):232-233.
[9]Borén J,Watts GF,Adiels M,et al.Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity:multicenter tracer kinetic study[J].Arterioscler Thromb Vasc Biol,2015,35(10):2218-2224.
[10]侯彦宏.载脂蛋白E基因敲除小鼠在动脉粥样硬化研究中的应用[J].心血管病学进展,2017,38(6):679-683.
[11]She ZG,Chang Y,Pang HB,et al.NG2 ablation reduces low-density lipoprotein retention of synthetic smooth muscle cells and atherogenesis[J].Arterioscler Thromb Vasc Biol,2016,36(1):49-59.
[12]Fogelstrand P,Borén J.Catch and release:NG2-coated vascular smooth muscle cells capture lipoproteins for macrophages[J].Arterioscler Thromb Vasc Biol,2015,36(1):7-8.
[13]Maus F,Sakry D,Biname F,et al.The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/Htr A2[J].PLoSOne,2015,10(9):e0137311.
[14]Rohatgi A,Khera A,Berry JD,et al.HDL cholesterol efflux capacity and incident cardiovascular events[J].N Engl J Med,2014,371(25):2383-2393.
[15]Li X,Tang WH,Mosior MK,et al.Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks[J].Arterioscler Thromb Vasc Biol,2013,33(7):1696-1705.
[16]Saleheen D,Scott R,Javad S,et al.Association of HDL cholesterol efflux capacity with incident coronary heart disease events:a prospective case-control study[J].Lancet Diabetes Endocrinol,2015,3(7):507-513.
[17]Williams KJ,Wu X.Imbalanced insulin action in chronic over nutrition:clinical harm,molecular mechanisms,and a way forward[J].Atherosclerosis,2016,247(4):225-282.
[18]Taskinen MR,Borén J.New insights into the pathophysiology of dyslipidemia in type 2 diabetes[J].Atherosclerosis,2015,239(2):483-495.
[19]Varbo A,Benn M,Tybjrg-Hansen A,et al.Remnant cholesterol as a causal risk factor for ischemic heart disease[J].J Am Coll Cardiol,2013,61(4):427-436.
[20]Blom DJ,Hala T,Bolognese M,et al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.
[21]Holman RR,Koren MJ,Roth E,et al.Evaluation of the glycemic effects and efficacy and safety of evolocumab(AMG 145)in subjects with or without dysglycemia or metabolic syndrome[J].Diabetes,2015,64(suppl.1):A68.
[22]尹纯,孙艺红.2型糖尿病血脂异常及治疗[J].心血管病学进展,2017,38(5):488-492.
[23]Xiao C,Dash S,Morgantini C,et al.Gut peptides are novel regulators of intestinal lipoprotein secretion:experimental and pharmacological manipulation of lipoprotein metabolism[J].Diabetes,2015,64(7):2310-2318.
[24]Adeli K,Lewis GF.Intestinal lipoprotein overproduction in insulin-resistant states[J].Curr Opin Lipidol,2008,19(3):221-228.
[25]李有中,谢康,冯敏,等.急性脑梗死与相关载脂蛋白关系的研究[J].中华全科医学,2013,11(11):1712-1797.
[26]Ye F,Liu J,Yang S,et a1.Higher apolipoprotein B levels are associated with earlier onset of first-ever atherosclerotic stroke[J].Int J Neurosci,2014,125(3):186-190.
[27]Pischon T,Girman CJ,Sacks FM,et al.Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men[J].Circulation,2005,112(22):3375-3383.
[28]Walldius G,Jungner I,Holmes I,et al.High apolipoprotein B,low apolipoprotein A-I,and improvement in the prediction of fatal myocardial infarction(AMORISstudy):a prospective study[J].Lancet,2001,358(9298):2026-2033.
[29]Walldius G,Aastveit AH,Jungner I.Stoke mortality and the apo B/apo A-I ratio:results of the AMORIS prospective study[J].J Intern Med,2006,259(3):259-266.
[30]Meisinger C,Loewel H,Mraz W,et al.Prognostic value of apolipoprotein build A-I in the prediction myocardial infarction in middle-aged men and women:results from the MONICA/KORA Augsburg cohort study[J].Eur Heart J,2005,26(3):271-278.
[31]Sniderman AD,Williams K,Contois JH,et al.A meta-analysis of low-density lipoprotein cholesterol,non-high-density lipoprotein cholesterol,and apolipoprotein B as markers of cardiovascular risk[J].Circ Cardiovasc Qual Outcomes,2011,4(3):337-345.
[32]Cannon CP,Blazing MA,Giugliano RP,et al.Ezetimibe added to statin therapy after acute coronary syndromes[J].N Engl J Med,2015,372(25):2387-2397.
[33]Jacobson TA.Opening a new lipid“apo-thecary”:incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk[J].Mayo Clin Proc,2011,86(6):762-780.
[2]Cannon CP,Blazing MA,Giugliano RP,et al.Ezetimibe added to statin therapy after acute coronary syndromes[J].N Engl J Med,2015,372(25):2387-2397.
[3]Robinson JG,Farnier M,Krempf M,et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1489-1499.
[4]Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509.
[5]Hegele RA,Gidding SS,Ginsberg HN,et al.Nonstatin low-density lipoproteinlowering therapy and cardiovascular risk reduction-statement from ATVB Council[J].Arterioscler Thromb Vasc Biol,2015,35(11):2269-2280.
[6]Williams KJ,Tabas I,Fisher EA.How an artery heals[J].Circ Res,2015,117(11):909-913.
[7]Borén J,Williams KJ.The central role of arterial retention of cholesterol rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis:a triumph of simplicity[J].Curr Opin Lipidol,2016,27(5):473-483.
[8]Tannock LR.Proteoglycan-LDL interactions:a novel therapeutic target?[J].Atherosclerosis,2014,233(1):232-233.
[9]Borén J,Watts GF,Adiels M,et al.Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity:multicenter tracer kinetic study[J].Arterioscler Thromb Vasc Biol,2015,35(10):2218-2224.
[10]侯彦宏.载脂蛋白E基因敲除小鼠在动脉粥样硬化研究中的应用[J].心血管病学进展,2017,38(6):679-683.
[11]She ZG,Chang Y,Pang HB,et al.NG2 ablation reduces low-density lipoprotein retention of synthetic smooth muscle cells and atherogenesis[J].Arterioscler Thromb Vasc Biol,2016,36(1):49-59.
[12]Fogelstrand P,Borén J.Catch and release:NG2-coated vascular smooth muscle cells capture lipoproteins for macrophages[J].Arterioscler Thromb Vasc Biol,2015,36(1):7-8.
[13]Maus F,Sakry D,Biname F,et al.The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/Htr A2[J].PLoSOne,2015,10(9):e0137311.
[14]Rohatgi A,Khera A,Berry JD,et al.HDL cholesterol efflux capacity and incident cardiovascular events[J].N Engl J Med,2014,371(25):2383-2393.
[15]Li X,Tang WH,Mosior MK,et al.Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks[J].Arterioscler Thromb Vasc Biol,2013,33(7):1696-1705.
[16]Saleheen D,Scott R,Javad S,et al.Association of HDL cholesterol efflux capacity with incident coronary heart disease events:a prospective case-control study[J].Lancet Diabetes Endocrinol,2015,3(7):507-513.
[17]Williams KJ,Wu X.Imbalanced insulin action in chronic over nutrition:clinical harm,molecular mechanisms,and a way forward[J].Atherosclerosis,2016,247(4):225-282.
[18]Taskinen MR,Borén J.New insights into the pathophysiology of dyslipidemia in type 2 diabetes[J].Atherosclerosis,2015,239(2):483-495.
[19]Varbo A,Benn M,Tybjrg-Hansen A,et al.Remnant cholesterol as a causal risk factor for ischemic heart disease[J].J Am Coll Cardiol,2013,61(4):427-436.
[20]Blom DJ,Hala T,Bolognese M,et al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.
[21]Holman RR,Koren MJ,Roth E,et al.Evaluation of the glycemic effects and efficacy and safety of evolocumab(AMG 145)in subjects with or without dysglycemia or metabolic syndrome[J].Diabetes,2015,64(suppl.1):A68.
[22]尹纯,孙艺红.2型糖尿病血脂异常及治疗[J].心血管病学进展,2017,38(5):488-492.
[23]Xiao C,Dash S,Morgantini C,et al.Gut peptides are novel regulators of intestinal lipoprotein secretion:experimental and pharmacological manipulation of lipoprotein metabolism[J].Diabetes,2015,64(7):2310-2318.
[24]Adeli K,Lewis GF.Intestinal lipoprotein overproduction in insulin-resistant states[J].Curr Opin Lipidol,2008,19(3):221-228.
[25]李有中,谢康,冯敏,等.急性脑梗死与相关载脂蛋白关系的研究[J].中华全科医学,2013,11(11):1712-1797.
[26]Ye F,Liu J,Yang S,et a1.Higher apolipoprotein B levels are associated with earlier onset of first-ever atherosclerotic stroke[J].Int J Neurosci,2014,125(3):186-190.
[27]Pischon T,Girman CJ,Sacks FM,et al.Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men[J].Circulation,2005,112(22):3375-3383.
[28]Walldius G,Jungner I,Holmes I,et al.High apolipoprotein B,low apolipoprotein A-I,and improvement in the prediction of fatal myocardial infarction(AMORISstudy):a prospective study[J].Lancet,2001,358(9298):2026-2033.
[29]Walldius G,Aastveit AH,Jungner I.Stoke mortality and the apo B/apo A-I ratio:results of the AMORIS prospective study[J].J Intern Med,2006,259(3):259-266.
[30]Meisinger C,Loewel H,Mraz W,et al.Prognostic value of apolipoprotein build A-I in the prediction myocardial infarction in middle-aged men and women:results from the MONICA/KORA Augsburg cohort study[J].Eur Heart J,2005,26(3):271-278.
[31]Sniderman AD,Williams K,Contois JH,et al.A meta-analysis of low-density lipoprotein cholesterol,non-high-density lipoprotein cholesterol,and apolipoprotein B as markers of cardiovascular risk[J].Circ Cardiovasc Qual Outcomes,2011,4(3):337-345.
[32]Cannon CP,Blazing MA,Giugliano RP,et al.Ezetimibe added to statin therapy after acute coronary syndromes[J].N Engl J Med,2015,372(25):2387-2397.
[33]Jacobson TA.Opening a new lipid“apo-thecary”:incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk[J].Mayo Clin Proc,2011,86(6):762-780.